Association between Interferon-Inducible Protein 6 (IFI6) Polymorphisms and Hepatitis B Virus Clearance.
- Author:
Geun Hee PARK
1
;
Kyoung Yeon KIM
;
Sung Won CHO
;
Jae Youn CHEONG
;
Gyeong Im YU
;
Dong Hoon SHIN
;
Kyu Bum KWACK
Author Information
- Publication Type:Original Article
- Keywords: hepatitis B virus; IFI6; single nucleotide polymorphism
- MeSH: Apoptosis; Fibrosis; Genotype; Hepatitis; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Diseases; Negotiating; Polymorphism, Single Nucleotide; T-Lymphocytes
- From:Genomics & Informatics 2013;11(1):15-23
- CountryRepublic of Korea
- Language:English
- Abstract: CD8+ T cells are key factors mediating hepatitis B virus (HBV) clearance. However, these cells are killed through HBV-induced apoptosis during the antigen-presenting period in HBV-induced chronic liver disease (CLD) patients. Interferon-inducible protein 6 (IFI6) delays type I interferon-induced apoptosis in cells. We hypothesized that single nucleotide polymorphisms (SNPs) in the IFI6 could affect the chronicity of CLD. The present study included a discovery stage, in which 195 CLD patients, including chronic hepatitis B (HEP) and cirrhosis patients and 107 spontaneous recovery (SR) controls, were analyzed. The genotype distributions of rs2808426 (C > T) and rs10902662 (C > T) were significantly different between the SR and HEP groups (odds ratio [OR], 6.60; 95% confidence interval [CI], 1.64 to 26.52, p = 0.008 for both SNPs) and between the SR and CLD groups (OR, 4.38; 95% CI, 1.25 to 15.26; p = 0.021 and OR, 4.12; 95% CI, 1.18 to 14.44; p = 0.027, respectively). The distribution of diplotypes that contained these SNPs was significantly different between the SR and HEP groups (OR, 6.58; 95% CI, 1.63 to 25.59; p = 0.008 and OR, 0.15; 95% CI, 0.04 to 0.61; p = 0.008, respectively) and between the SR and CLD groups (OR, 4.38; 95% CI, 1.25 to 15.26; p = 0.021 and OR, 4.12; 95% CI, 1.18 to 14.44; p = 0.027, respectively). We were unable to replicate the association shown by secondary enrolled samples. A large-scale validation study should be performed to confirm the association between IFI6 and HBV clearance.
